Drug intelligence / Profile preview

Ticalopride

Development stage: Unknown
Modality: Small Molecules

Overview

Ticalopride is an isomer of the active metabolite of cisapride. It acts as a serotonin 5-HT4 receptor agonist, which increases acetylcholine release in the enteric nervous system, specifically the myenteric plexus. This action leads to increased tone and amplitude of gastric contractions, relaxation of the pyloric sphincter and duodenal bulb, and increased peristalsis of the duodenum and jejunum, resulting in accelerated gastric emptying and intestinal transit.

Other names: (+)-Norcisapride202590-69-04-amino-5-chloro-2-methoxy-n-[(3s,4r)-3-methoxypiperidin-4-yl]benzamide

Targets

HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on Ticalopride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ticalopride.

Explore the full profile